JAK/TYK2
Dr. Jack Cush reviews the news, journal reports, ACR and FDA announcements from the past week on RheumNow.com
First In Class, TYK2 Inhibitor FDA Approved for Psoriasis
2022 New ACR Guidance…
2 years 1 month ago
EULAR recommendations for management of #RheumatoidArthritis
6️⃣Glucocorticoids should be tapered & discontinued as soon as clinically feasible
8️⃣JAKi can be used but consider risk factors
via Prof Smolen #EULAR2022 https://t.co/7cocPSpgkH
2 years 1 month ago
#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/kTn4rxMlej
Bags are packed, ready to go, but wait there’s more abstracts to show.
The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest…
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic…
At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA).
How do PsA patients do on csDMARDs and is the time to switch or escalate to biologics the same as…
2 years 1 month ago
Deucravacitinib: TYK2 inhibitor in pts with active SLE
Phase 2, randomized, double blind, placebo-controlled study
Met primary endpoint SRI response across all doses
No death, MACE, VTE, systemic infections
@RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee
2 years 1 month ago
Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change.
In the 2022 version:
JAKi now separate sentence following bDMARDs, with proviso to mention risk.
Sometimes guidelines have to tell us what we’ve all inevitably been expecting
#EULAR2022 @RheumNow https://t.co/RPbPNi3vcW
2 years 1 month ago
In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA.
@RheumNow #EULAR2022 ABST#POS0331 https://t.co/pNL3Zlgmt7
Podcasts
Location, Location, Location (7.26.2024)-
The Best Rheumatologists (7.19.2024)
-
Pollution And Autoimmunity (7.12.2024)
Poster Hall